- Home
- MVO vs CRVO Comparison
MVO vs CRVO Comparison
Compare MVO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- CRVO
- Stock Information
- Founded
- MVO 2006
- CRVO 2001
- Country
- MVO United States
- CRVO United States
- Employees
- MVO N/A
- CRVO N/A
- Industry
- MVO Oil & Gas Production
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- MVO Energy
- CRVO Health Care
- Exchange
- MVO Nasdaq
- CRVO Nasdaq
- Market Cap
- MVO 66.6M
- CRVO 67.4M
- IPO Year
- MVO N/A
- CRVO N/A
- Fundamental
- Price
- MVO $5.78
- CRVO $5.56
- Analyst Decision
- MVO
- CRVO Strong Buy
- Analyst Count
- MVO 0
- CRVO 8
- Target Price
- MVO N/A
- CRVO $25.57
- AVG Volume (30 Days)
- MVO 55.1K
- CRVO 137.9K
- Earning Date
- MVO 01-01-0001
- CRVO 08-08-2025
- Dividend Yield
- MVO 17.46%
- CRVO N/A
- EPS Growth
- MVO N/A
- CRVO N/A
- EPS
- MVO 1.46
- CRVO N/A
- Revenue
- MVO N/A
- CRVO $9,308,215.00
- Revenue This Year
- MVO N/A
- CRVO N/A
- Revenue Next Year
- MVO N/A
- CRVO N/A
- P/E Ratio
- MVO $7.29
- CRVO N/A
- Revenue Growth
- MVO N/A
- CRVO 15.14
- 52 Week Low
- MVO $8.85
- CRVO $1.80
- 52 Week High
- MVO $13.95
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- MVO 49.03
- CRVO 30.87
- Support Level
- MVO $5.55
- CRVO $6.31
- Resistance Level
- MVO $5.94
- CRVO $7.20
- Average True Range (ATR)
- MVO 0.24
- CRVO 0.53
- MACD
- MVO -0.01
- CRVO -0.10
- Stochastic Oscillator
- MVO 32.39
- CRVO 0.00
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.